General

Dr. Simrit Parmar, an associate professor in the College of Medicine at Texas A&M University and founder of the clinical-stage biotech company Cellenkos Inc. in Houston, has invented a new cell therapy that shows strong promise for the treatment of ALS, aplastic anemia and other devastating diseases.

Matica Biotechnology, a leading CDMO specializing in cell and gene therapies (CGT), has announced a strategic partnership with the National Center for Therapeutics Manufacturing (NCTM), a part of the Texas A&M Engineering Experiment Station.

A new company is coming to town, and along with it, local leaders say they expect local technology and innovation to challenge growth capitals in California.

Texas A&M University has been named one of Fast Company magazine’s Most Innovative Companies for 2025, joining business icons including Nvidia, YouTube and EA Sports.

COLLEGE STATION, Texas (KBTX) - A new partnership between Matica Biotechnology in College Station and Childs Cure Genetic Research is bringing hope to families affected by rare genetic disorders.

COLLEGE STATION, Texas (KBTX) - The Texas A&M Board of Regents met Thursday to take action on several key items on their agenda.

Texas A&M is setting the standard in research security and innovation, officials told the university’s Board of Regents during a meeting on Wednesday.

College Station-Bryan is ranked No. 21 nationally in the Heartland Institute’s ranking of the country’s Most Dynamic Metropolitans, announced on Thursday. The College Station-Bryan metro ranks No. 4 in the 20 central states the think tank defines as America’s “heartland.”

(KBTX) - Local business leaders and city officials gathered for the Bryan-College Station Economic Outlook Conference, where experts shared their predictions for the region’s 2025 economy, and growth is on the horizon.

College Station is the No. 6 U.S. Growth City of 2024, according to the U-Haul Growth Index analyzing one-way customer moves over the past year. College Station earned the same growth ranking for 2023.